PCN reports : psychiatry and clinical neurosciences · 2026
Valbenazine induced acute parkinsonism in a patient with alcohol use disorder and central pontine myelinolysis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Nagai Yasuhito, Mamiko Miyata, Miyakawa Koichi
Аннотация
BACKGROUND: Valbenazine is used to treat dyskinesia and is generally associated with limited side effects; however, a few cases with the adverse effect of parkinsonism are reported in the literature. In this study, we report a case of valbenazine-induced acute parkinsonism.
CASE PRESENTATION: The patient was a 60-year-old male who suffered from depression and alcohol use disorder. When he was 50 years old, he was diagnosed with Wernicke's encephalopathy, central pontine myelinolysis-induced parkinsonism, and dyskinesia. After remission, dyskinesia persisted and was diagnosed as tardive dyskinesia. The patient was treated with tetrabenazine and valbenazine at different times, and only valbenazine treatment induced acute parkinsonism.
CONCLUSION: Valbenazine can cause acute parkinsonism, even in patients who have previously tolerated tetrabenazine, and especially in those with underlying basal ganglia lesions.
CASE PRESENTATION: The patient was a 60-year-old male who suffered from depression and alcohol use disorder. When he was 50 years old, he was diagnosed with Wernicke's encephalopathy, central pontine myelinolysis-induced parkinsonism, and dyskinesia. After remission, dyskinesia persisted and was diagnosed as tardive dyskinesia. The patient was treated with tetrabenazine and valbenazine at different times, and only valbenazine treatment induced acute parkinsonism.
CONCLUSION: Valbenazine can cause acute parkinsonism, even in patients who have previously tolerated tetrabenazine, and especially in those with underlying basal ganglia lesions.